Who are Besremi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Saphnelo, Plegridy, Pegasys, Avonex, Betaseron, Plegridy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ropeginterferon-alfa-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Besremi — Competitive Intelligence Brief

Besremi (ROPEGINTERFERON ALFA-2B) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alfa-2b [EPC]. Area: Rare Disease.

marketed Interferon alfa-2b [EPC] Interferon alpha/beta receptor Rare Disease Recombinant protein Live · refreshed every 30 min

Target snapshot

Besremi (ROPEGINTERFERON ALFA-2B) — Pharma Essentia Corporation. Besremi works by binding to the interferon alpha/beta receptor, triggering a signaling cascade that reduces red blood cell production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Besremi TARGET	ROPEGINTERFERON ALFA-2B	Pharma Essentia Corporation	marketed	Interferon alfa-2b [EPC]	Interferon alpha/beta receptor	2021-01-01
Saphnelo	ANIFROLUMAB	AstraZeneca	marketed	Type I Interferon Receptor Antagonist [EPC]	Interferon alpha/beta receptor 1	2021-01-01
Plegridy	PEGINTERFERON BETA-1A	Biogen Idec Inc	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	2014-01-01
Pegasys	PEGINTERFERON ALFA-2A	Hoffman-La Roche	marketed		Interferon alpha/beta receptor	2002-01-01
Avonex	INTERFERON BETA-1A	Biogen	marketed	Interferon beta [EPC]	Interferon alpha/beta receptor	1996-01-01
Betaseron	INTERFERON BETA-1B	Bayer Healthcare Pharms	marketed	Interferon beta	Interferon alpha/beta receptor	1993-01-01
Plegridy	Plegridy	Holy Name Medical Center, Inc.	marketed		Interferon alpha/beta receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alfa-2b [EPC] class)

Pharma Essentia Corporation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Besremi — Competitive Intelligence Brief. https://druglandscape.com/ci/ropeginterferon-alfa-2b. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab